

CTI BIOPHARMA, CORP.

Special Meeting of Shareholders on January 24, 2018

Final Report and Certificate of the Inspector of Election

I, the undersigned, the duly appointed Inspector of Election at the Special Meeting of Shareholders (the “**Meeting**”) of CTI BioPharma, Corp., a Washington corporation (the “**Company**”), held on Wednesday, January 24, 2018, hereby certify that:

1. before entering upon the discharge of my duties as Inspector of Election at the Meeting, I took and signed an Oath of Inspector of Election;
2. the Meeting was held at the office of the Company located at 3101 Western Avenue, Suite 800, Seattle, Washington 98121, on Wednesday, January 24, 2018, at 10:00 a.m. Pacific Daylight Time (PDT), pursuant to notice duly given;
3. at the close of business on December 5, 2018, the record date for the determination of shareholders entitled to vote at the Meeting (the “**Record Date**”), there were issued and outstanding 42,968,066 shares of the Company’s common stock, no par value per share (the “**Common Stock**”), each share of Common Stock being entitled to one vote and constituting all of the outstanding voting securities of the Company as of the Record Date, and there were issued and outstanding 575 shares of the Company’s Series N-3 Preferred Stock (the “**Preferred Stock**”), no share of Preferred Stock being entitled to vote;
4. at the Meeting, the holders of 18,634,354 shares of the Common Stock, representing 43.36% of the issued and outstanding shares of Common Stock, were present in person or represented by proxy, and a quorum was present at the Meeting for all matters voted on during the Meeting;
5. the undersigned canvassed the votes of the shareholders cast by ballot or proxy on the matters presented at the Meeting;
6. at the Meeting, the votes cast for, against or abstaining from, and the broker non-votes with respect to the proposal to approve the reincorporation of the Company from the State of Washington to the State of Delaware by merging the Company into a newly formed, wholly-owned Delaware subsidiary (“**Proposal 1**”), were as follows:

No. of Shares Voted For	% of Voted Shares Voted For	No. of Shares Voted Against	% of Voted Shares Voted Against	No. of Abstentions	No. of Broker Non-Vote
18,489,913	99.22%	56,486	0.3%	87,955	0

7. at the Meeting, the votes cast for, against or abstaining from, and the broker non-votes with respect to the proposal to approve the adjournment of the special meeting, if necessary (“**Proposal 2**”), were as follows:

No. of Shares Voted For	% of Voted Shares Voted For	No. of Shares Voted Against	% of Voted Shares Voted Against	No. of Abstentions	No. of Broker Non-Vote
18,476,602	99.15%	116,410	0.62%	41,342	0

IN WITNESS WHEREOF, I, the undersigned, have made this Final Report and have hereunto set my hand this 24th day of June, 2018.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Eric Sibbitt", written in black ink.

Eric Sibbitt, Esq.
of O'Melveny & Myers LLP